Mark E Molitch
Overview
Explore the profile of Mark E Molitch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
7907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Limonte C, Gao X, Bebu I, Seegmiller J, Lorenzi G, Perkins B, et al.
Kidney Int Rep
. 2024 May;
9(5):1406-1418.
PMID: 38707816
Introduction: Tubular biomarkers may shed insight into progression of kidney tubulointerstitial pathology complementary to traditional measures of glomerular function and damage. Methods: We examined trajectories of tubular biomarkers in the...
2.
Upadrasta G, Affinati A, Kumar S, Zelada H, Fulkerson C, Gupta S, et al.
Clin Transplant
. 2024 Jan;
38(1):e15239.
PMID: 38289889
Infection and rejection outcomes were retrospectively analyzed in patients following liver transplant and separately following heart transplant with patients being stratified by their severity of immediate postoperative insulin resistance as...
3.
Yuen K, Ghalib L, Buchfelder M, Hughes J, Langlois F, Molitch M
Endocr Pract
. 2023 Dec;
30(3):282-291.
PMID: 38160940
Objective: To describe a practical approach of when and how often to perform imaging, and when to stop imaging pituitary adenomas (PAs). Methods: A literature review was carried out and...
4.
Molitch M, Tripputi M, Levey A, Crandall J, Dabelea D, Herman W, et al.
J Diabetes Complications
. 2023 Aug;
37(9):108556.
PMID: 37607422
Aims: We analyzed the incidence of kidney disease in the Diabetes Prevention Program Outcomes Study (DPPOS) by originally randomized treatment group assignment: Intensive Lifestyle (ILS), Metformin (MET) or Placebo (PLB)....
5.
Bebu I, Braffett B, de Boer I, Aiello L, Bantle J, Lorenzi G, et al.
Diabetes Care
. 2022 Dec;
46(2):361-368.
PMID: 36520643
Objective: To describe the relationships between the cumulative incidences of long-term complications in individuals with type 1 diabetes (T1D) and assess whether observed associations are independent of age, duration of...
6.
Navarro J, Sanchez A, Ba Aqeel S, Ye M, Rehman M, Wysocki J, et al.
Kidney Int Rep
. 2022 Dec;
7(12):2657-2667.
PMID: 36506234
Introduction: Angiotensinogen (AOG) is the precursor of peptides of the renin angiotensin system (RAS). Because insulin up-regulates transcriptional factors that normally repress kidney AOG synthesis, we evaluated urinary AOG (uAOG)...
7.
Samson S, Nachtigall L, Fleseriu M, Jensterle M, Manning P, Elenkova A, et al.
Eur J Endocrinol
. 2022 Sep;
187(6):733-741.
PMID: 36173649
Objective: The objective of this study is to report results from the open-label extension (OLE) of the OPTIMAL trial of oral octreotide capsules (OOC) in adults with acromegaly, evaluating the...
8.
Molitch M
Lancet Diabetes Endocrinol
. 2022 Aug;
10(10):682-683.
PMID: 36007537
No abstract available.
9.
Molitch M
Lancet Diabetes Endocrinol
. 2022 Jul;
10(9):614-616.
PMID: 35870477
No abstract available.
10.
Molitch M
Pituitary
. 2022 May;
25(5):733-736.
PMID: 35507245
Mifepristone is the only glucocorticoid receptor antagonist currently approved for the treatment of Cushing's syndrome. Although originally developed as an abortifacient due to its blockade of the progesterone receptor, a...